Table 2.
Evaluated Cut-off | P Value | Potential Early Recurrence Cohort |
Potential Late Recurrence Cohort |
||||||
---|---|---|---|---|---|---|---|---|---|
N | RFS (mo) | PRS (mo) | OS (mo) | n | RFS (mo) | PRS (mo) | OS (mo) | ||
| |||||||||
3 mo | 3.43×10–1 | 85 | 1.6 | 7.9 | 9.1 | 604 | 13.7 | 7.5 | 23.7 |
4 mo | 1.10×10–2 | 123 | 2.1 | 6.9 | 9.8 | 630 | 14.6 | 7.7 | 24.4 |
5 mo | 6.79×10–4 | 157 | 2.6 | 6.5 | 9.2 | 596 | 15.1 | 7.9 | 25.1 |
6 mo | 8.70×10–5 | 182 | 3.3 | 6.5 | 9.9 | 571 | 15.6 | 8.0 | 25.9 |
7 mo | 1.70×10–5 | 222 | 3.8 | 6.5 | 10.1 | 531 | 16.6 | 8.0 | 26.6 |
8 mo | 3.73×10–7 | 244 | 4.0 | 6.4 | 10.2 | 509 | 17.1 | 8.3 | 28.1 |
9 mo | 1.29×10–9 | 277 | 4.4 | 6.1 | 10.7 | 476 | 18.1 | 8.9 | 29.6 |
10 mo | 1.68×10–11 | 319 | 5.3 | 6.0 | 11.2 | 434 | 19.4 | 9.7 | 31.5 |
11 mo | 2.56×10–11 | 353 | 5.9 | 6.2 | 12.3 | 400 | 20.2 | 10.3 | 32.5 |
12 mo | 3.31×10–13 | 388 | 6.5 | 6.1 | 13.0 | 365 | 20.9 | 10.8 | 34.6 |
13 mo | 4.21×10–13 | 410 | 6.8 | 6.2 | 13.6 | 343 | 23.0 | 10.8 | 35.6 |
14 mo | 6.9810–13 | 437 | 7.1 | 6.2 | 13.9 | 316 | 24.5 | 10.9 | 38.5 |
15 mo | 3.47×10–12 | 462 | 7.5 | 6.4 | 14.4 | 291 | 25.7 | 10.6 | 40.2 |
16 mo | 1.49×10–12 | 489 | 8.4 | 6.6 | 14.9 | 264 | 26.9 | 10.9 | 43.3 |
17 mo | 4.75×10–11 | 508 | 8.6 | 6.7 | 15.2 | 204 | 27.6 | 11.7 | 44.9 |
18 mo | 3.58×10–12 | 526 | 8.9 | 6.7 | 15.7 | 227 | 29.0 | 11.8 | 47.8 |
19 mo | 1.21×10–11 | 543 | 9.1 | 6.9 | 16.0 | 210 | 30.6 | 12.1 | 48.4 |
20 mo | 4.21×10–11 | 564 | 9.3 | 6.9 | 16.6 | 189 | 31.9 | 13.4 | 51.3 |
Shown in bold is the optimal cut-off threshold with the lowest P value. RFS indicates recurrence-free survival; PRS, post-recurrence survival; OS, overall survival.